legislation: 115-s-3565

Congressional bills and resolutions from Congress.gov, filtered to policy areas relevant to environmental, health, agriculture, and wildlife regulation.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

bill_id congress bill_type bill_number title policy_area introduced_date latest_action_date latest_action_text origin_chamber sponsor_name sponsor_state sponsor_party sponsor_bioguide_id cosponsor_count summary_text update_date url
115-s-3565 115 s 3565 Opioid Advocacy Transparency Act of 2018 Health 2018-10-10 2018-10-10 Read twice and referred to the Committee on Finance. Senate Sen. McCaskill, Claire [D-MO] MO D M001170 1 Opioid Advocacy Transparency Act of 2018 This bill expands reporting requirements related to the ownership and investment interests of certain patient-advocacy organizations. Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a "covered recipient," defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of "covered recipient," for purposes of this requirement, to also include patient-advocacy organizations that advocate on issues related to opioids. Furthermore, with respect to transfers of value to such organizations, the bill subjects not only manufacturers but also pharmaceutical trade associations to the reporting requirement. 2023-01-11T13:41:09Z  

Links from other tables